

**Date of publication:** 31 March 2014

**Implementation:** To be determined by each Service

## **Change Notification UK National Blood Services No. 3 - 2014**

### **Alitretinoin**

**Applies to the Tissue Donor Selection Guidelines Live Donors, Tissue Donor Selection Guidelines Deceased Donors, Cord Blood Donor Selection Guidelines and Bone Marrow and PBSC Donor Selection Guidelines**

#### **New Entry:**

<b>Obligatory</b>	Must not donate if less than four weeks from the last dose of Alitretinoin (Toctino).
<b>Additional Information</b>	<p>Alitretinoin is a drug analogous to Tretinoin and Isotretinoin used to treat acne and refractory eczema.</p> <p>Treatment with retinoids such as Alitretinoin can cause birth defects for babies exposed to them before birth. It is important to allow time for the drug to be cleared from the donor. A one month deferral for donation is recommended in the drug information sheet.</p>
<b>See if relevant</b>	<u>Acne</u> <u>Dermatitis</u>
<b>Reason for change</b>	New entry.

### **Toctino**

#### **New Entry:**

<b>See</b>	<u>Alitretinoin</u>
<b>Reason for change</b>	New entry.

**\Continued**

**Please modify the entries to the various Donor Selection Guidelines as follows:**

## Acne

**Applies to the Tissue Donor Selection Guidelines Live Donors**

<b>Obligatory</b>	<b>Must not donate if:</b> a) Has ever taken Etretinate (Tigason). b) Less than 24 months from the last dose of Acitretin (Neotigason). c) Less than four weeks from the last dose of Isotretinoin (Roaccutane) or Alitretinoin (Toctino). d) There is secondary infection
<b>Discretionary</b>	Therapy with topical treatments, oral tetracycline, erythromycin and Dianette (cyproterone acetate and ethinyloestradiol), accept.
<b>Additional Information</b>	Etretinate (Tigason), Acitretin (Neotigason), Isotretinoin (Roaccutane) and Alitretinoin (Toctino) can cause birth defects in babies exposed to them while inside the womb. It is important to allow time for the drug to be cleared from the donor. It takes longer to clear some drugs than others. Secondary infection of acne is usually obvious with swelling and redness of affected spots. There is a risk of bacteria entering the blood. This could be a serious threat to anybody receiving tissues. This is because the bacteria can multiply to dangerous levels.
<b>Reason for change</b>	To include information on Alitretinoin (Toctino).

## Dermatitis

**Applies to the Tissue Donor Selection Guidelines Live Donors**

<b>See if relevant</b>	<u><a href="#">Alitretinoin</a></u> <u><a href="#">Infection – General</a></u> <u><a href="#">Steroid Therapy</a></u>
<b>Reason for change</b>	To add a link to Alitretinoin.

**\Continued**

# Acne

## Applies to the Tissue Donor Selection Guidelines Deceased Donors

<b>Obligatory</b>	<b>Must not donate if:</b> a) Has ever taken Etreinate (Tigason). b) Less than 24 months from the last dose of Acitretin (Neotigason). c) Less than four weeks from the last dose of Isotretinoin (Roaccutane) or Alitretinoin (Toctino). d) There is secondary infection
<b>Discretionary</b>	<b>1. All tissues</b> Therapy with topical treatments, oral tetracycline, erythromycin and Dianette (cyproterone acetate and ethinyloestradiol), accept. <b>2. Eyes</b> If no ocular surface disease and corneas are to be stored by organ culture, accept even if treated with Etreinate (Tigason), Acitretin (Neotigason), Isotretinoin (Roaccutane) or Alitretinoin (Toctino).
<b>Additional Information</b>	Etreinate (Tigason), Acitretin (Neotigason), Isotretinoin (Roaccutane) and Alitretinoin (Toctino) can cause birth defects in babies exposed to them while inside the womb. It is important to allow time for the drug to be cleared from the donor. It takes longer to clear some drugs than others. Secondary infection of acne is usually obvious with swelling and redness of affected spots. There is a risk of bacteria entering the blood. This could be a serious threat to anybody receiving tissues. This is because the bacteria can multiply to dangerous levels.  <b>Eyes.</b> For corneas stored by organ culture (but not for corneas stored at 4°C) there is an opportunity to detect contaminating bacteria in the tissue and it should be safe to donate. Secondary infection of the lid margin (blepharitis) on its own should not preclude eye donation, but donations must not be taken if there is also ocular surface disease.
<b>Reason for change</b>	To include information on Alitretinoin (Toctino).

# Dermatitis

## Applies to the Tissue Donor Selection Guidelines Deceased Donors

<b>Obligatory</b>	<b>Skin Donation</b> <b>Must not donate:</b> Areas of affected skin.
-------------------	--

**\Continued**

<b>Discretionary</b>	<b>Other tissues:</b> If no other contraindication, accept
<b>See if relevant</b>	<u>Alitretinoin</u> <u>Infection – General</u> <u>Steroid Therapy</u>
<b>Reason for change</b>	To add a link to Alitretinoin.

## Acne

### Applies to the Bone Marrow and PBSC Donor Selection Guidelines

<b>Obligatory</b>	<b>Must not donate if:</b> a) Has ever taken Etretinate (Tigason). b) Less than 24 months from the last dose of Acitretin (Neotigason). c) Less than four weeks from the last dose of Isotretinoin (Roaccutane) or Alitretinoin (Toctino). d) There is secondary infection
<b>Discretionary</b>	Therapy with topical treatments, oral tetracycline, erythromycin and Dianette (cyproterone acetate and ethinyloestradiol), accept.
<b>Additional Information</b>	Etretinate (Tigason), Acitretin (Neotigason), Isotretinoin (Roaccutane) and Alitretinoin (Toctino) can cause birth defects in babies exposed to them while inside the womb. It is important to allow time for the drug to be cleared from the donor. It takes longer to clear some drugs than others. Secondary infection of acne is usually obvious with swelling and redness of affected spots. There is a risk of bacteria entering the blood. This could be a serious threat to anybody receiving tissues. This is because the bacteria can multiply to dangerous levels.
<b>Reason for change</b>	To include information on Alitretinoin (Toctino).

## Dermatitis

### Applies to the Bone Marrow and PBSC Donor Selection Guidelines

<b>Obligatory</b>	<b>Must not donate if:</b> a) Venepuncture or harvest site is affected. b) Using systemic therapy
<b>Discretionary</b>	If the area affected is small the venepuncture or harvest site is unaffected and using topical treatment only, accept

**\Continued**

<b>See if relevant</b>	<u>Alitretinoin</u> <u>Allergy</u> <u>Infection – General</u> <u>Steroid Therapy</u>
<b>Reason for change</b>	To add a link to Alitretinoin.

## Acne

### Applies to the Cord Blood Donor Selection Guidelines

<b>Obligatory</b>	<b>Must not donate if:</b> a) Has ever taken Etretinate (Tigason). b) Pregnancy commenced within 24 months of the last dose of Acitretin (Neotigason). c) Pregnancy commenced within four weeks of the last dose of Isotretinoin (Roaccutane) or Alitretinoin (Toctino). d) There is secondary infection
<b>Discretionary</b>	Therapy with topical treatments, oral tetracycline, erythromycin and Dianette (cyproterone acetate and ethinyloestradiol), accept.
<b>Additional Information</b>	Etretinate (Tigason), Acitretin (Neotigason), Isotretinoin (Roaccutane) and Alitretinoin (Toctino) can cause birth defects in babies exposed to them while inside the womb. It is important to allow time for the drug to be cleared from the donor. It takes longer to clear some drugs than others. Secondary infection of acne is usually obvious with swelling and redness of affected spots. There is a risk of bacteria entering the blood. This could be a serious threat to anybody receiving tissues. This is because the bacteria can multiply to dangerous levels.
<b>Reason for change</b>	To include information on Alitretinoin (Toctino).

## Dermatitis

### Applies to the Cord Blood Donor Selection Guidelines

<b>Obligatory</b>	<b>Must not donate if:</b> Mother has infected perineal dermatitis
<b>See if relevant</b>	<u>Alitretinoin</u> <u>Allergy</u> <u>Infection – General</u> <u>Steroid Therapy</u>

**\Continued**

**Reason for change** To add a link to Alitretinoin.

*SmacLennan*

Dr Sheila MacLennan  
Professional Director - Joint UKBTS Professional Advisory Committee  
☎ Direct Dial: (0113) 820 8638    ✉ sheila.maclennan@nhsbt.nhs.uk